Spyre Therapeutics

Update in progress

SYRE (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company focused on therapies for inflammatory bowel disease (IBD) and rheumatic diseases. It is developing SPY001, a humanized IgG1 antibody in Phase 2 that targets the α4β7 integrin for IBD; SPY002 and SPY072, anti-TL1A antibodies; SPY003, an IL-23–targeting program in Phase 2; and combinations SPY120 (anti-α4β7/TL1A), SPY130 (anti-α4β7/IL-23), and SPY230 (anti-TL1A/IL-23). Formerly Aeglea BioTherapeutics, it renamed Spyre in Nov 2023 and is based in Waltham, MA, founded 2013.

Company score

Sentiment: 0.37; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.19; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive